16 found
Order:
Disambiguations
Stephanie M. Fullerton [15]Stephanie Malia Fullerton [1]
  1.  44
    Broad Consent for Research With Biological Samples: Workshop Conclusions.Christine Grady, Lisa Eckstein, Ben Berkman, Dan Brock, Robert Cook-Deegan, Stephanie M. Fullerton, Hank Greely, Mats G. Hansson, Sara Hull, Scott Kim, Bernie Lo, Rebecca Pentz, Laura Rodriguez, Carol Weil, Benjamin S. Wilfond & David Wendler - 2015 - American Journal of Bioethics 15 (9):34-42.
    Different types of consent are used to obtain human biospecimens for future research. This variation has resulted in confusion regarding what research is permitted, inadvertent constraints on future research, and research proceeding without consent. The National Institutes of Health Clinical Center's Department of Bioethics held a workshop to consider the ethical acceptability of addressing these concerns by using broad consent for future research on stored biospecimens. Multiple bioethics scholars, who have written on these issues, discussed the reasons for consent, the (...)
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark   42 citations  
  2.  25
    Informed Consent in Translational Genomics: Insufficient Without Trustworthy Governance.Wylie Burke, Laura M. Beskow, Susan Brown Trinidad, Stephanie M. Fullerton & Kathleen Brelsford - 2018 - Journal of Law, Medicine and Ethics 46 (1):79-86.
    No categories
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   3 citations  
  3.  54
    Has the biobank bubble burst? Withstanding the challenges for sustainable biobanking in the digital era.Don Chalmers, Dianne Nicol, Jane Kaye, Jessica Bell, Alastair V. Campbell, Calvin W. L. Ho, Kazuto Kato, Jusaku Minari, Chih-Hsing Ho, Colin Mitchell, Fruzsina Molnár-Gábor, Margaret Otlowski, Daniel Thiel, Stephanie M. Fullerton & Tess Whitton - 2016 - BMC Medical Ethics 17 (1):1.
    _BMC Medical Ethics_ is an open access journal publishing original peer-reviewed research articles in relation to the ethical aspects of biomedical research and clinical practice, including professional choices and conduct, medical technologies, healthcare systems and health policies. _BMC __Medical Ethics _is part of the _BMC_ series which publishes subject-specific journals focused on the needs of individual research communities across all areas of biology and medicine. We do not make editorial decisions on the basis of the interest of a study or (...)
    Direct download (8 more)  
    Translate
     
     
    Export citation  
     
    Bookmark   4 citations  
  4.  25
    Parents’ Attitudes Toward Consent and Data Sharing in Biobanks: A Multisite Experimental Survey.Armand H. Matheny Antommaria, Kyle B. Brothers, John A. Myers, Yana B. Feygin, Sharon A. Aufox, Murray H. Brilliant, Pat Conway, Stephanie M. Fullerton, Nanibaa’ A. Garrison, Carol R. Horowitz, Gail P. Jarvik, Rongling Li, Evette J. Ludman, Catherine A. McCarty, Jennifer B. McCormick, Nathaniel D. Mercaldo, Melanie F. Myers, Saskia C. Sanderson, Martha J. Shrubsole, Jonathan S. Schildcrout, Janet L. Williams, Maureen E. Smith, Ellen Wright Clayton & Ingrid A. Holm - 2018 - Ajob Empirical Bioethics 9 (3):128-142.
    No categories
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  5.  1
    Diversity and Inclusion in Unregulated mHealth Research: Addressing the Risks.Shawneequa Callier & Stephanie M. Fullerton - 2020 - Journal of Law, Medicine and Ethics 48 (1_suppl):115-121.
    mHealth devices and applications, with their wide accessibility and ease of use, have the potential to address persistent inequities in biomedical research participation. Yet, while mHealth technologies may facilitate more inclusive research participation, negative features of some unregulated use in research — misleading enrollment practices, the promotion of secondary mHealth applications, discriminatory profiling, and poorer quality feedback due to dependencies on biased data and algorithms — may threaten the trust and engagement of underrepresented individuals and communities. To maximize the participation (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  6.  23
    Racialized Genetics and the Study of Complex Diseases: The Thrifty Genotype Revisited.Yin Paradies, M. J. Montoya & Stephanie M. Fullerton - 2007 - Perspectives in Biology and Medicine 50 (2):203-227.
  7.  45
    Secondary Uses and the Governance of de-Identified Data: Lessons From the Human Genome Diversity Panel.Stephanie M. Fullerton & Sandra S.-J. Lee - 2011 - BMC Medical Ethics 12 (1):16.
    Background: Recent changes to regulatory guidance in the US and Europe have complicated oversight of secondary research by rendering most uses of de-identified data exempt from human subjects oversight. To identify the implications of such guidelines for harms to participants and communities, this paper explores the secondary uses of one de-identified DNA sample collection with limited oversight: the Human Genome Diversity Project (HGDP)-Centre d'Etude du Polymorphisme Humain, Fondation Jean Dausset (CEPH) Human Genome Diversity Panel. Methods: Using a combination of keyword (...)
    Direct download (12 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  8.  13
    No Panacea: Next-Gen Sequencing Will Not Mitigate Adoptees’ Lack of Genetic Family Health History.Stephanie M. Fullerton - 2016 - American Journal of Bioethics 16 (12):41-43.
  9.  67
    Race-Based Medicine and Justice as Recognition: Exploring the Phenomenon of BiDil.Joon-ho Yu, Sara Goering & Stephanie M. Fullerton - 2009 - Cambridge Quarterly of Healthcare Ethics 18 (1):57.
    In the United States, health disparities have been framed by categories of race. Racial health disparities have been documented for cardiovascular disease, cancer, diabetes, HIV/AIDS, and numerous other diseases and measures of health status. Although such disparities can be read as symptoms of disparities in healthcare access, pervasive social and economic inequities, and discrimination, some have suggested that the disparities might be due, at least in part, to biological differences based on race. Or, to be more precise, if race itself (...)
    Direct download (7 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  10.  16
    Relationships with Test-Tubes: Where's the Reciprocity?Kelly Fryer-Edwards & Stephanie M. Fullerton - 2006 - American Journal of Bioethics 6 (6):36 – 38.
  11.  20
    Looking for Trouble and Finding It.Susan B. Trinidad, Stephanie M. Fullerton & Wylie Burke - 2015 - American Journal of Bioethics 15 (7):15-17.
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  12.  12
    Sharing Data and Experience: Using the Clinical and Translational Science Award (CTSA) “Moral Community” to Improve Research Ethics Consultation.Maureen Kelley, Kelly Fryer-Edwards, Stephanie M. Fullerton, Thomas H. Gallagher & Benjamin Wilfond - 2008 - American Journal of Bioethics 8 (3):37 – 39.
  13.  13
    Beneficence, Clinical Urgency, and the Return of Individual Research Results to Relatives.Stephanie M. Fullerton, Susan Brown Trinidad, Gail P. Jarvik & Wylie Burke - 2012 - American Journal of Bioethics 12 (10):9-10.
    The American Journal of Bioethics, Volume 12, Issue 10, Page 9-10, October 2012.
    Direct download (4 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  14.  20
    On the Absence of Biology in Philosophical Considerations of Race.Stephanie Malia Fullerton - 2007 - In Shannon Sullivan Nancy Tuana (ed.), Race and Epistemologies of Ignorance.
  15.  13
    Patients' Choices for Return of Exome Sequencing Results to Relatives in the Event of Their Death.Laura M. Amendola, Martha Horike‐Pyne, Susan B. Trinidad, Stephanie M. Fullerton, Barbara J. Evans, Wylie Burke & Gail P. Jarvik - 2015 - Journal of Law, Medicine and Ethics 43 (3):476-485.
    The informed consent process for genetic testing does not commonly address preferences regarding disclosure of results in the event of the patient's death. Adults being tested for familial colorectal cancer were asked whether they want their exome sequencing results disclosed to another person in the event of their death prior to receiving the results. Of 78 participants, 92% designated an individual and 8% declined to. Further research will help refine practices for informed consent.
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  16.  20
    Review of Inmaculada de Melo-Martin, Taking Biology Seriously: What Biology Can & Cannot Tell Us About Moral & Public Policy Issues. [REVIEW]Suzanne Holland & Stephanie M. Fullerton - 2007 - American Journal of Bioethics 7 (10):47 – 48.